Fundraising FoxNeurocentrx Pharma Ltd
1 known investors
Find your way into Neurocentrx Pharma Ltd
Sign up to see every warm intro you have to Neurocentrx Pharma Ltd
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Neurocentrx Pharma Ltd team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Neurocentrx is developing NRCx-201, an investigational drug-and-software combination product that pairs an abuse-deterrent ketamine capsule with prescription safety software to deliver regulated ketamine-based depression care. The product targets psychiatrists and patients with treatment-resistant major depressive disorder and bipolar II depression, aiming for FDA approval for use in both clinical and home-care settings.
Investors · 1
Frequently asked questions
- What does Neurocentrx Pharma Ltd do?
- Neurocentrx is developing NRCx-201, an investigational drug-and-software combination product that pairs an abuse-deterrent ketamine capsule with prescription safety software to deliver regulated ketamine-based depression care. The product targets psychiatrists and patients with treatment-resistant major depressive disorder and bipolar II depression, aiming for FDA approval for use in both clinical and home-care settings.
- Who are Neurocentrx Pharma Ltd's investors?
- Neurocentrx Pharma Ltd's investors include O2h Ventures.